ASX:CUV Clinuvel Pharmaceuticals (CUV) Stock Price, News & Analysis → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free CUV Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume124,193 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield0.33%Price TargetN/A Stock AnalysisStock Analysis Get Clinuvel Pharmaceuticals alerts: Email Address Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Clinuvel PharmaceuticalsClinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.Read More Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details CUV Stock News HeadlinesMarch 5, 2024 | finance.yahoo.comMalibu shines a light on CLINUVEL’s pioneering work in photomedicineMarch 4, 2024 | msn.comDr Boreham’s Crucible: Does Clinuvel’s investor value run deeper than just ‘makes Scenesse’?April 27, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)February 28, 2024 | morningstar.comClinuvel Pharmaceuticals Ltd CUVFebruary 22, 2024 | fool.com.auWhy Clinuvel, Medibank, Sayona Mining, and Tabcorp shares are sinking todayFebruary 22, 2024 | msn.comAustralia stocks higher at close of trade; S&P/ASX 200 up 0.04%January 3, 2024 | msn.comShort & Caught: Pilbara Minerals ASX’s most shorted as lithium stocks targetedDecember 7, 2023 | fool.com.auLooking for ASX growth shares to buy? These could rise ~30%April 27, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)September 20, 2023 | fool.com.auDown 25% in a month, is this ASX 300 company about to sue the UK Government?September 1, 2023 | fool.com.auWhy the Clinuvel Pharmaceuticals share price crashed 11% lower todaySeptember 1, 2023 | markets.businessinsider.comWilsons Sticks to Its Buy Rating for Clinuvel Pharmaceuticals Limited (CLVLF)May 4, 2023 | markets.businessinsider.comClinuvel Pharmaceuticals Limited (CLVLF) Gets a Buy from WilsonsApril 21, 2023 | msn.comWILSONS Maintains Clinuvel Pharmaceuticals (ASX:CUV) Overweight RecommendationApril 16, 2023 | finance.yahoo.comInstitutions own 21% of Clinuvel Pharmaceuticals Limited (ASX:CUV) shares but individual investors control 54% of the companyApril 4, 2023 | markets.businessinsider.comWilsons Sticks to Their Buy Rating for Clinuvel Pharmaceuticals Limited (CLVLF)March 14, 2023 | finance.yahoo.comHere's Why We Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention TodayFebruary 7, 2023 | reuters.comCUV.AX - | Stock Price & Latest News | ReutersFebruary 1, 2023 | finance.yahoo.comCLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned IndividualsJanuary 16, 2023 | finanznachrichten.deClinuvel Pharmaceuticals Limited: CLINUVEL Trial Results Show Drug Reduces DNA DamageNovember 24, 2022 | finance.yahoo.comClinuvel Pharmaceuticals Limited's (ASX:CUV) Stock Has Fared Decently: Is the Market Following Strong Financials?November 18, 2022 | afr.comClinuvel Pharmaceuticals LimitedNovember 7, 2022 | finance.yahoo.comWhile institutions own 21% of Clinuvel Pharmaceuticals Limited (ASX:CUV), individual investors are its largest shareholders with 54% ownershipOctober 20, 2022 | finance.yahoo.comClinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Is Looking A Bit Stretched At The MomentAugust 31, 2022 | fool.com.auWhy did this ASX 200 healthcare share rocket 16% today?July 27, 2022 | fool.com.auWhy CLINUVEL and these ASX shares have doubled in value in 12 monthsJuly 18, 2022 | fool.com.auClinuvel Pharmaceuticals shares higher on strong quarterly sales growthSee More Headlines Receive CUV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clinuvel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:CUV CUSIPN/A CIKN/A Webwww.clinuvel.com Phone61 3 9660 4900FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A$0.57 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$30.15 million Net Margins36.88% Pretax MarginN/A Return on Equity18.98% Return on Assets14.71% Debt Debt-to-Equity Ratio0.60 Current Ratio6.86 Quick Ratio10.03 Sales & Book Value Annual Sales$81.76 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow19.36 Book ValueA$3.61 per share Price / BookN/AMiscellaneous Outstanding Shares50,130,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.74 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Philippe Jacques Wolgen M.B.A. (Age 61)M.D., CEO, MD & Director Comp: $2.78MMr. Darren Michael Keamy B.Com. (Age 51)CPA, CFO & Company Secretary Comp: $415.08kDr. Dennis J. WrightChief Scientific OfficerMr. Lachlan HayDirector of Global OperationsMr. Malcolm BullHead of Australian Operations & Investor RelationsDr. Rose Quadbeck-DielSenior Vice President of Regulatory AffairsDr. Azza HamilaHead of Quality & Drug SafetyMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersPhilippe WolgenSold 1,212,625 sharesTotal: $20.61 M ($17.00/share)Philippe WolgenBought 1,850 shares on 9/19/2023Total: $29,812.75 ($16.12/share)Philippe WolgenSold 3,120,715 sharesTotal: $53.89 M ($17.27/share) CUV Stock Analysis - Frequently Asked Questions How often does Clinuvel Pharmaceuticals pay dividends? What is the dividend yield for Clinuvel Pharmaceuticals? Clinuvel Pharmaceuticals declared a Final dividend on Monday, September 4th. Shareholders of record on Tuesday, September 19th will be given a dividend of 0.05 per share on Tuesday, September 19th. This represents a dividend yield of 0.28%. The ex-dividend date is Monday, September 4th. This is a boost from the stock's previous Final dividend of A$0.04. Read our dividend analysis for CUV. Is Clinuvel Pharmaceuticals a good dividend stock? Clinuvel Pharmaceuticals (ASX:CUV) pays an annual dividend of A$0.05 per share and currently has a dividend yield of 0.33%. The dividend payout ratio is 8.77%. This payout ratio is at a healthy, sustainable level, below 75%. Read our dividend analysis for CUV. What other stocks do shareholders of Clinuvel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clinuvel Pharmaceuticals investors own include Zynga (ZNGA), Worldpay (WP), VolitionRx (VNRX), REA Group (REA), CSL (CSL), Cochlear (COH), Afterpay (APT). This page (ASX:CUV) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace4 Cryptos BETTER than BitcoinTrue Market InsidersThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clinuvel Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
